ABOUT

OUR COMPANY

About Onconova Therapeutics

Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. The Company is actively studying rigosertib in clinical trials, and has conducted trials with two other research compounds. Onconova also has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300.

Advanced clinical trials with our lead compound, rigosertib, are aimed at unmet medical needs of patients with myelodysplastic syndromes (MDS). MDS is a hematological malignancy resulting in bone marrow failure which leads to acute myeloid leukemia (AML) in 30% of high-risk patients. There have been no advancements in this indication in more than a decade. Current therapeutic options are not curative and often cause serious side effects. More than 10,000 patients suffer from MDS in the USA, representing a significant unmet medical need.

Onconova Therapeutics was incorporated in 1998 in Delaware and began trading on the NASDAQ stock exchange under the ticker symbol ONTX in July, 2013.

Mission Statement

We are committed to delivering novel solutions to cancer patients in need. We seek to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.

Management Team

Onconova Therapeutics is advised by a group of thought leaders with significant expertise in targeted cancer therapeutics, clinical development, and commercialization.

Steven M. Fruchtman, M.D.
President & CEO

Dr. Fruchtman joined Onconova in January 2015 as Chief Medical Officer. He was promoted to President in July 2018 and to President & CEO in January 2019. He has extensive experience in large and small biopharmaceutical companies and has led successful clinical development programs while serving in senior positions at Ortho Biotech Products, Novartis, Allos Therapeutics, Spectrum Pharmaceuticals and Syndax Pharmaceuticals.

Previously, Dr. Fruchtman was on the faculty of the Mount Sinai School of Medicine and the Director of the Stem Cell Transplantation and Myeloproliferative Disorder Programs at Mount Sinai Hospital in New York City. He is an author of more than 170 lectures, presentations, books, chapters, and abstracts and serves as an external reviewer for multiple medical journals.

Dr. Fruchtman received his medical degree from New York Medical College with the distinction of membership in the Alpha Omega Alpha honorary medical fraternity.

Mark Guerin
Chief Financial Officer

Mr. Guerin joined Onconova Therapeutics in September 2013 to augment the financial reporting, forecasting, and internal controls capabilities of the company following the IPO in July 2013. Prior to joining Onconova, Mr. Guerin worked as an interim senior finance & accounting executive facilitating the post-acquisition integration activities of newly-acquired private equity portfolio companies.

Previously, Mr. Guerin was the VP Finance & CFO of Cardiokine, Inc. through that company’s filing of a New Drug Application and the sale of the company. Prior to joining Cardiokine, Mr. Guerin was Director, Financial Reporting & Internal Controls at Barrier Therapeutics, Inc. during Barrier’s IPO and follow-on offering. Mr. Guerin started his career at Coopers & Lybrand in Philadelphia. He received his bachelor’s degree in Accounting from DeSales University and has earned the CPA, CMA, and CFM professional certifications.

Ric Woodman, M.D.
Chief Medical Officer and Senior Vice President,
Research & Development

Richard “Ric” Woodman, M.D., joined Onconova as Chief Medical Officer in November 2018. Prior to joining Onconova, Dr. Woodman served as Senior Vice President and Head of U.S. Clinical Development and Medical Affairs (USCDMA) which is responsible for all phase IB-IV oncology/hematology clinical programs. Ric provided strategic medical and scientific leadership for both marketed and development-stage compounds.

Previously, Ric served as Franchise Head for Hematology in Global Medical Affairs at Novartis Oncology. His responsibilities included global oversight of non-registration clinical programs and studies for Tasigna(r), Glivec(r), Odomzo(r), Panobinostat(r), Midostaurin(r) and CTL019. Before joining Novartis Oncology, Dr. Woodman was Senior Medical Director with Johnson & Johnson leading the Oncology franchise at Ortho Biotech Products, LP, where he supervised both investigator- and company-sponsored oncology and hematology studies for Procrit(r) in the U.S.

Dr. Woodman joined the faculty of the University of Calgary in Canada in 1990 and held appointments as Professor in the Departments of Medicine and Oncology and was a full member in the Immunology Research Group. He served as Acting Head for the Division of Hematology and Hematological Malignancies for the University of Calgary and Calgary Health Region, and acted as a consultant in adult and pediatric hematology at the Alberta Children’s Hospital, Tom Baker Cancer Center, Foothills Medical Center, and Calgary Laboratory Services.

Dr. Woodman completed a postdoctoral research fellowship at Scripps Clinic and Research Institute in the Department of Experimental Medicine, and has authored more than 90 peer-reviewed publications in the areas of hematology and immunology. He received his medical degree from the University of Calgary in June 1981.

Manoj Maniar, Ph.D.
Senior Vice President, Product Development

Dr. Maniar received his B.S. in Pharmacy from Bombay College of Pharmacy and his Ph.D. in Pharmaceutics from the University of Connecticut. He has led the development and commercialization of several pharmaceutical products and medical devices during his career. Prior to joining Onconova, Dr. Maniar was with SRI International, where he served as Senior Director, Formulations and Drug Delivery. He has authored more than 100 patents, publications, and presentations in the field of pharmaceutical sciences.

Avi Oler
Vice President, Corporate Development & General Counsel

Mr. Avi Oler joined Onconova’s Management Team in December 2018 as Vice President, Corporate Development and General Counsel. Mr. Oler is primarily responsible for business development, investor relations, and legal affairs of the Company.

Mr. Oler served most recently as Vice President of Operations and Chief of Staff to the CEO of Spectrum Pharmaceuticals. During his tenure, he was instrumental in the company’s progress and productive licensing activities. He served in varied roles of increasing responsibility, as a member of the executive management team, the corporate development team, and as Head of Alliances and Legal Affairs. Due to a series of successful accomplishments, he was named Chief of Staff.

Previously, Mr. Oler practiced corporate law at the law firm of Kirkland & Ellis LLP. Prior to this, he was a financial research analyst at the Center for Financial Research & Analysis, and an investment banker with Lehman Brothers in London.

Mr. Oler holds a JD from Northwestern University School of Law with Distinction, an MBA from Kellogg School of Management with Distinction, and a Master of Science in Politics of the World Economy from the London School of Economics. He earned his undergraduate degrees, magna cum laude, from the Wharton School and the University of Pennsylvania.

Board of Directors

A group of thought leaders with significant expertise in targeted cancer therapeutics, clinical development, and commercialization.

Michael B. Hoffman
Chairman

Mr. Hoffman is the Founder and Partner at Stone Capital Partners, a private equity firm focused on power and renewable energy. Before founding Stone Capital Partners, Mr. Hoffman was a Partner of Riverstone, where he was principally responsible for investments in power and renewable energy for Riverstone’s funds. Riverstone is an energy and power-focused private equity firm with approximately $37 billion of equity capital raised across seven investment funds, including the world’s largest renewable energy fund. Mr. Hoffman was co-head of Riverstone’s Renewable Energy Funds I and II, and responsible for all power investments in its six conventional energy funds, with equity capital commitments of approximately $6 billion. Before joining Riverstone in 2003, Mr. Hoffman was senior managing director and head of the mergers and acquisitions advisory business of The Blackstone Group for fifteen years.

In addition to serving as the Chairman of Onconova Therapeutics, Mr. Hoffman is also Chairman of QR Pharma, a company developing compounds for neurodegenerative disorders such as Parkinsons and Alzheimers; he serves as Chairman and Founder of Curative BioTherapeutics, which is developing oncology drugs in the CAR-T and antibody space for AML; and in February 2014, Mr. Hoffman joined the Board of Rockefeller University and is on Rockefeller’s Tech Transfer Committee.

Mr. Hoffman is a co-author of the book, Green: Your Place in the New Energy Revolution.

Mr. Hoffman received his B.A. and M.A. from Northwestern University and his M.B.A. from Harvard Business School. He is married to Jane Steiner Hoffman and has two children.

Steven M. Fruchtman, M.D.
President & CEO

Dr. Fruchtman received his medical degree from New York Medical College with the distinction of membership in the Alpha Omega Alpha honorary medical fraternity.

Jerome Groopman, M.D.

Dr. Groopman holds the Dina and Raphael Recanati Chair of Medicine at the Harvard Medical School and is Chief of Experimental Medicine at the Beth Israel Deaconess Medical Center. He received his B.A. from Columbia College summa cum laude and his M.D. from Columbia College of Physicians and Surgeons in New York where he was elected to AOA. He served his internship and residency in internal medicine at the Massachusetts General Hospital, then his specialty fellowships in hematology and oncology at the University of California and Harvard Medical School. Dr. Groopman chaired the Advisory Committee to the FDA for Biological Response Modifiers. He serves on several scientific editorial boards and has published many research papers. He was elected to the Institute of Medicine of the National Academy of Sciences in 2000. Dr. Groopman’s research has focused on blood development, cancer, and AIDS, and he has been a major participant in the development of many AIDS-related therapies. He is a staff writer for The New Yorker and has written for The New York Times and The Washington Post. He is author of “The Measure of Our Days” (1997), “Second Opinions” (2000), “The Anatomy of Hope” (2004), and the recently released, “How Doctors Think.” “The Measure of Our Days,” explores the spiritual lives of patients with serious illness and was the basis for the ABC Television series “Gideon’s Crossing.

James J. Marino, Esq.

Mr. Marino was a Partner at the global law firm of Dechert LLP for 28 years where he served as Managing Partner of the Princeton Office. During this period, he advised numerous leading life science companies in connection with financings, acquisitions and strategic alliances. Mr. Marino served as the outside counsel for Onconova from its inception through and including its initial public offering. Previously, he served on the Board of Directors of Pharmacopeia Drug Discovery, Inc. from 2000-2006 and has worked in advisory capacities and on the boards of multiple non-profit organizations, including Robert Wood Johnson University Hospital. Mr. Marino was one of the co-founders of BioNJ, a trade association of biotech companies, which he has represented since 1994. He currently serves on the Board of Trustees of Wake Forest University and Wake Forest Baptist Medical Center. Mr. Marino received his B.A., J.D. and MBA from Rutgers University.

Viren Mehta, Pharm.D.

Dr. Mehta, Managing Member of Mehta Partners, has over thirty years of experience in the pharmaceutical and biotechnology industry, investment research, strategic advisory services, and asset management. Prior to founding Mehta and Isaly, where he pioneered an in-depth valuation methodology for biotechnology companies, Dr. Mehta was a part of the strategic planning team of the International Division at Merck & Co. Dr. Mehta earned a Doctor of Pharmacy at the University of Southern California, and an M.B.A. Degree from the Anderson School of Business at the University of California, Los Angeles.

E. Premkumar Reddy, Ph.D.
Founder, Lead Scientific Advisor

Dr. Reddy is a renowned scientist with a specific interest in molecular oncology. He is a Professor in the Department of Oncological Sciences & Department of Structural & Chemical Biology at the Mount Sinai School of Medicine in New York. Dr. Reddy is a pioneer in the understanding of the molecular basis of cancer and the development of novel anti-cancer strategies. He is the author of more than 200 publications and several dozen patent applications. Dr. Reddy founded Onconova Therapeutics in 1998. He was a co-editor of the international journal of cancer research, Oncogene, published by Nature Publishing Group. Among Dr. Reddy’s many accomplishments are the co-invention of a diagnostic procedure used in HIV AIDS testing and the novel drug candidates being developed by Onconova.

Jack E. Stover

Since December 2015, Mr. Stover has served as Interim President and CEO of Interpace Diagnostics Group, Inc., formerly known as “PDI, Inc.”, and has served on their board of directors since August 2005. He was the chair of PDI’s audit committee from August 2005 until December 2015. Mr. Stover has been Chief Executive Officer of Zebec Therapeutics LLC (“Zebec”) since April 2014. Zebec is the successor to Quadrant Pharmaceuticals LLC, which Mr. Stover co-founded and was President and Director of from September 2013. From 2009 to February 2012, Mr. Stover served as the executive chairman of Targeted Nano Therapeutics LLC, a privately held biotechnology company focused on targeted delivery of peptides and proteins. Mr. Stover was also chairman of the audit committee and a member of the board of directors of Arbios Systems Inc. from 2005 to 2008 and a member of the board of directors of Influmedix, Inc. from 2010 to 2011. From 2004 to 2008, he served as chief executive officer, president and director of Antares Pharma, Inc., a publicly held specialty pharmaceutical company listed on the American Stock Exchange. Prior to that, Mr. Stover was executive vice president and chief financial officer of Sicor, Inc., a publicly held company which manufactured and marketed injectable pharmaceutical products, and which was acquired by Teva Pharmaceutical Industries. Prior to that, Mr. Stover was executive vice president and director of a proprietary women’s pharmaceutical company, Gynetics, Inc. (“Gynetics”), and before Gynetics, he was senior vice president and director of B. Braun Medical, Inc., a private global medical device and pharmaceutical company. For more than five years prior to that, Mr. Stover was a partner with PricewaterhouseCoopers (then Coopers and Lybrand), working in the bioscience industry division in New Jersey. Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant.

Scientific Advisory Board

Onconova Therapeutics is advised by a group of thought leaders with significant expertise in targeted cancer therapeutics, clinical development, and commercialization.

Alan R. Williamson, Ph.D.
Chairman

Dr. Williamson has extensive experience in pharmaceutical discovery. He served as Vice President of Basic Research and Vice President, Research Strategy Worldwide, for Merck. Previously he was with Glaxo, UCLA, University of Glasgow, and the National Institute for Medical Research, U.K. He is the recipient of the Colworth Medal of the Biochemical Society and a member of the EMBL. He was elected Fellow of the Royal Society of Edinburgh in 1976 and Fellow of the Institute of Biology in 1982. Dr. Williamson sits on the scientific advisory board of Illumina. He is a consultant to the venture capital firm Abingworth Management Ltd.

David R. Parkinson, M.D.
Venture Partner at NEA

Dr. Parkinson is a Venture Partner at New Enterprise Associates (NEA). From 2007 to 2012, Dr. Parkinson served as President and CEO of Nodality Inc., a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and decision-making. Previously, Dr. Parkinson was Senior Vice President, Oncology Research and Development at Biogen Idec. At Biogen he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he had served as Vice President, Oncology Development, at Amgen and Vice President, Global Clinical Oncology Development at Novartis. During his tenures at Amgen and Novartis Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec^®, Femara^®, Zometa^®, Kepivance^®, and Vectibix^®. Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program, before leaving for Novartis. He has also held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center of Tufts University School of Medicine. He received his M.D. as gold medalist from the University Of Toronto Faculty Of Medicine in 1977, with Internal Medicine and Hematology/Oncology training in Montreal at McGill University and in Boston at New England Medical Center. Dr. Parkinson is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA’s Cody Medal. He is a past President of the International Society of Biological Therapy, and past Editor of the Journal of Immunotherapy. He currently serves on the National Cancer Policy Forum of the Institute of Medicine and is a member of the FDA’s Science Board. He was recently elected to the Board of Directors of the American Association of Cancer Research, and he continues to serve as Chairman of the AACR Finance Committee.

George F. Vande Woude, Ph.D.
Van Andel Research Institute

Dr. Vande Woude served as research virologist for the US Department of Agriculture at Plum Island Animal Disease Center prior to his career at the National Cancer Institute (NCI) where he served successively as Head of the Human Tumor Studies and Virus Tumor Biochemistry Sections, Chief of the Laboratory of Molecular Oncology, and Director of the Advanced Bioscience Laboratories-Basic Research Program. He was Special Advisor to the Director of NCI and served to reorganize the intramural basic science at NCI. In 1999, he was selected to be the first Director of the newly created Van Andel Research Institute in Grand Rapids, Michigan. Dr. Vande Woude is the recipient of many awards honoring his contributions, is author of over 250 scientific research articles and over 60 articles in books or monographs, and is a member of the National Academy of Sciences.

Ross C. Donehower, M.D.
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Dr. Donehower is Professor of Oncology, the Director of Medical Oncology/Hematology Fellowship Training program and a Director in the Division of Medical Oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. His current clinical interests lie in gastrointestinal cancers and drug development. Dr. Donehower performed his postgraduate training in internal medicine at Johns Hopkins, and has worked at the U.S. Public Health Service and at the National Cancer Institute in Bethesda. He is currently director of both the Division of Medical Oncology in the Department of Oncology and of the Medical Oncology Fellowship Training Program at the Johns Hopkins Kimmel Comprehensive Cancer Center as well as a Professor of Oncology and Medicine. Dr. Donehower performed pioneering work in clinical studies of paclitaxel (Taxol^®), one of the most important chemotherapy agents developed in the last several decades.

Stephen Nimer, M.D.
Sylvester Comprehensive Cancer Center at the University of Miami Hospitals and Clinics

Dr. Nimer is a Professor of Medicine, Biochemistry & Molecular Biology and Director at the Sylvester Comprehensive Cancer Center at the University of Miami Hospitals and Clinics. He received his medical degree from the University of Chicago Pritzker School of Medicine and completed his Internship and Residency in Internal Medicine at the University of California-Los Angeles (UCLA) School of Medicine, where he was named Chief Medical Resident. He remained at UCLA for his Fellowship in Hematology and Oncology. Dr. Nimer is a Fellow of the American College of Physicians and a member of the American Society for Clinical Investigation, the American Society of Hematology, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is on the editorial boards of several journals, such as Leukemia Research and the American Journal of Oncology Review. He is a reviewer for the New England Journal of Medicine, Blood, and Nature Medicine. Dr. Nimer has published over 120 research articles and given numerous presentations at scientific meetings.

Anna Marie Skalka, Ph.D.
Fox Chase Cancer Center

Dr. Skalka is Professor, W.W. Smith Chair in Cancer Research and Senior Advisor to the President at the Fox Chase Cancer Center in Philadelphia. She is a leading expert in the molecular biology of retroviruses and the molecular basis of cancer. In recognition of her outstanding accomplishments, Dr. Skalka has been elected as a Fellow to the American Academy of Microbiology, the American Association for the Advancement of Science, the American Academy of Arts and Science, and the New York Academy of Science.

ABOUT

About Onconova Therapeutics

Mission Statement

Management Team

Board of Directors

Scientific Advisory Board

Onconova Therapeutics

GET IN TOUCH

ABOUT ONCONOVA